A detailed history of Alyeska Investment Group, L.P. transactions in Argenx Se stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 60,000 shares of ARGX stock, worth $33.9 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
60,000
Previous 134,935 55.53%
Holding current value
$33.9 Million
Previous $58 Million 43.92%
% of portfolio
0.18%
Previous 0.35%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $32.5 Million - $41.4 Million
-74,935 Reduced 55.53%
60,000 $32.5 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $2.02 Million - $2.57 Million
5,686 Added 4.4%
134,935 $58 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $37.7 Million - $43.6 Million
-105,587 Reduced 44.96%
129,249 $50.9 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $79.6 Million - $119 Million
234,836 New
234,836 $89.3 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $5.01 Million - $6.05 Million
15,000 New
15,000 $5.59 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $5.43 Million - $6.27 Million
-15,831 Reduced 22.51%
54,500 $19.2 Million
Q2 2022

Aug 15, 2022

SELL
$269.58 - $378.88 $4.14 Million - $5.82 Million
-15,365 Reduced 17.93%
70,331 $26.6 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $11.5 Million - $15.9 Million
45,325 Added 112.27%
85,696 $27 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $2.79 Million - $3.63 Million
10,271 Added 34.12%
40,371 $14.1 Million
Q4 2017

Feb 14, 2018

SELL
$22.57 - $63.56 $2.06 Million - $5.8 Million
-91,213 Reduced 75.19%
30,100 $1.9 Million
Q3 2017

Nov 14, 2017

BUY
$19.81 - $22.61 $2.4 Million - $2.74 Million
121,313
121,313 $2.74 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.